Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 28, 2025
The
incidence
and
mortality
rates
of
liver
cancer
in
China
remain
elevated.
Although
early-stage
is
amenable
to
surgical
resection,
a
significant
proportion
patients
are
diagnosed
at
advanced
stages.
Currently,
addition
resection
for
hepatocellular
carcinoma,
the
primary
treatment
modalities
predominantly
include
chemotherapy.
widespread
use
chemotherapy,
which
non-selectively
targets
both
malignant
healthy
cells,
often
results
substantial
immunosuppression.
Simultaneously,
accumulation
chemotherapeutic
agents
can
readily
induce
drug
resistance
upon
reaching
physiological
threshold,
thereby
diminishing
efficacy
these
treatments.
Besides
there
exist
targeted
therapy,
immunotherapy
other
therapeutic
approaches.
Nevertheless,
development
remains
an
inevitable
challenge.
To
address
challenges,
we
turn
nanomedicine,
emerging
widely
utilized
discipline
that
significantly
influences
medical
imaging,
antimicrobial
strategies,
delivery
systems,
related
areas.
Stable
safe
nanomaterials
serve
as
effective
carriers
delivering
anticancer
drugs.
They
enhance
precision
targeting,
improve
bioavailability,
minimize
damage
cells.
This
review
focuses
on
common
nanomaterial
used
carcinoma
(HCC)
over
past
five
years.
following
summary
three
drugs:
Sorafenib,
Gefitinib,
lenvatinib.
Each
employs
distinct
result
varying
levels
release
rates,
efficacy.
Bioactive Materials,
Год журнала:
2024,
Номер
39, С. 544 - 561
Опубликована: Май 30, 2024
Once
bone
metastasis
occurs
in
lung
cancer,
the
efficiency
of
treatment
can
be
greatly
reduced.
Current
mainstream
treatments
are
focused
on
inhibiting
cancer
cell
growth
and
preventing
destruction.
Microwave
ablation
(MWA)
has
been
used
to
treat
tumors.
However,
MWA
may
damage
surrounding
normal
tissues.
Therefore,
it
could
beneficial
develop
a
nanocarrier
combined
with
microwave
metastasis.
Herein,
microwave-responsive
nanoplatform
(MgFe
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 28, 2025
The
incidence
and
mortality
rates
of
liver
cancer
in
China
remain
elevated.
Although
early-stage
is
amenable
to
surgical
resection,
a
significant
proportion
patients
are
diagnosed
at
advanced
stages.
Currently,
addition
resection
for
hepatocellular
carcinoma,
the
primary
treatment
modalities
predominantly
include
chemotherapy.
widespread
use
chemotherapy,
which
non-selectively
targets
both
malignant
healthy
cells,
often
results
substantial
immunosuppression.
Simultaneously,
accumulation
chemotherapeutic
agents
can
readily
induce
drug
resistance
upon
reaching
physiological
threshold,
thereby
diminishing
efficacy
these
treatments.
Besides
there
exist
targeted
therapy,
immunotherapy
other
therapeutic
approaches.
Nevertheless,
development
remains
an
inevitable
challenge.
To
address
challenges,
we
turn
nanomedicine,
emerging
widely
utilized
discipline
that
significantly
influences
medical
imaging,
antimicrobial
strategies,
delivery
systems,
related
areas.
Stable
safe
nanomaterials
serve
as
effective
carriers
delivering
anticancer
drugs.
They
enhance
precision
targeting,
improve
bioavailability,
minimize
damage
cells.
This
review
focuses
on
common
nanomaterial
used
carcinoma
(HCC)
over
past
five
years.
following
summary
three
drugs:
Sorafenib,
Gefitinib,
lenvatinib.
Each
employs
distinct
result
varying
levels
release
rates,
efficacy.
